Modifying the Function of Receptors that Drive Inflammatory Disease
A new class of anti-inflammatory drugs that modify Protease-Activated Receptor signaling (PARmodulins)
Parmodulins are small molecules that can selectively block certain aspects of inflammation while promoting anti-inflammatory signals mediated by protease-activated receptor 1 (PAR1).
We are Translating Innovative Research into Novel Therapeutics
Protease-Activated Receptors (PARs) drive inflammatory responses in kidney disease and other disorders. Preclinical investigations are underway to develop optimal parmodulins to safely treat a range of inflammation-driven diseases.
A Seasoned Team to Fight Inflammation-Driven Disease
Function Therapeutics was established based on compounds and assays in the lab of founder Dr. Chris Dockendorff, complemented by research from collaborators including those at Harvard Medical School, Leipzig University, Versiti Blood Research Institute, and the Medical College of Wisconsin. Our executive team and advisors have decades of experience in medicinal chemistry, pharmacology, drug development, and PAR biology.
Impact in Numbers
Of cardiac surgery patients in a retrospective study possessed criteria of acute kidney injury (2)
Current drugs for chronic kidney disease able to reverse renal damage
FDA-approved drugs to prevent acute kidney injury
FDA-approved drugs for sepsis